LKT Labs continues to expand its catalog with six new compounds for the new year… the first of many additions in store for 2018!
P327211 Pifithrin-α Hydrobromide: Inhibitor of p53 that may also inhibit other signaling pathways including heat shock and glucocorticoid.
P327212 Pifithrin-α-cyclic Hydrobromide: A more stable and less cytotoxic analog of pifithrin-alpha.
B030966 BAY 11-7082: Potential inhibitor of NF-kB, and many components of inflammatory signaling pathways including PI3K/Akt/IKK/NFkB, ERK/JNK/AP-1, TBK1/IRF-3, and Jak-2/STAT-1.
R183731 Resiquimod: An imidazoquinoline compound that is a TLR7/8 agonist.
L337521 Linagliptin: A dipeptidyl peptidase 4 inhibitor glucose-lowering compound with low risk of inducing hypoglycaemia.
E499601 Empagliflozin: A sodium glucose cotransporter 2 inhibitor found to ameliorate glucose intolerance and insulin resistance.